サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552489

爪真菌症の世界市場、規模、シェア、動向、産業分析レポート：タイプ別、治療別、地域別 - 市場予測、2024年～2032年

Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Market Forecast, 2024 - 2032.

出版日
ページ情報
英文 115 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
爪真菌症の世界市場、規模、シェア、動向、産業分析レポート：タイプ別、治療別、地域別 - 市場予測、2024年～2032年
出版日: 2024年08月01日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の爪真菌症市場規模は2032年までに56億8,946万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

爪真菌症市場は、真菌症に対する認識の高まりと一般市民の意識の向上により、大きな成長を遂げています。これにより、爪真菌症などの真菌感染症の早期発見や影響に対する理解が深まっています。

2023年9月、米国疾病予防管理センター（CDC）は真菌症啓発週間（FDAW）を認定しました。毎年、CDCとそのパートナーは、真菌感染症に対する一般の人々の意識を高めるための取り組みやアウトリーチ活動に参加しています。2023年のFDAWに向けて、様々なイベントで真菌症が増大する課題、複雑さ、重大な影響を強調しています。

さらに、レーザーは食品医薬品局（FDA）から承認を得ており、技術の進歩により爪真菌症の治療にレーザーが使用されるようになり、市場の拡大に寄与しています。

Indian Dermatology Online Journalによると、外用療法とフラクショナルCO2レーザーを組み合わせることで、爪真菌症治療の効果を高めることができます。爪甲の厚さ、爪真菌症の範囲と種類、セッションの回数、同時治療など、いくつかの要因が治療結果に影響を与えます。フラクショナルCO2レーザー治療は、爪に開口部を作ることで、42日間で外用ドラッグデリバリーを3～4倍改善します。したがって、爪真菌症に対する外用療法と並行して、前処置としてフラクショナルCO2レーザーを使用することは有益です。

さらに、爪真菌症に対する内服治療は、外用抗真菌薬に比べて成功率が高く、治療期間が短いため、患者の間で人気が高まっています。この真菌症に対する主な治療は塩酸テルビナフィンの内服です。多くのジェネリックメーカーが、増加する爪真菌症に対応するため、経口治療薬を発売しています。

例えば、2021年6月、Glenmark Pharmaceuticals社は、爪真菌症治療薬として450mgと300mgのテオフィリン徐放錠があり、治療上同等で生物学的に同等であるとして米国FDAから承認を得た。

爪真菌症市場レポートハイライト

遠位爪甲下爪真菌症セグメントが市場を独占。これは、爪真菌症治療により効果的な薬剤に対する需要の高まりを受けて、FDAによる承認数が増加しているためです。

局所治療薬は副作用が少ないため、予測期間中、局所治療薬セグメントが市場を独占しました。

予測期間中、北米地域が市場を独占したのは、対象疾患の発生が増加し、政府の政策が支持されたためです。

アジア太平洋地域は、医療サービスへのアクセスが限られており、衛生習慣が悪く、都市化が進んでいるため、CAGRが最も早いと予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の爪真菌症市場の洞察

  • 市場スナップショット
  • 爪真菌症市場力学
    • 促進要因と機会
      • 局所療法の需要の高まりが市場の成長を牽引
      • 先進技術の台頭が市場の成長を牽引
    • 抑制要因と課題
      • 代替療法の存在
  • PESTEL分析
  • 爪真菌症市場のアプリケーション動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の爪真菌症市場：タイプ別

  • 主な調査結果
  • イントロダクション
  • 遠位爪甲下爪真菌症
  • 近位爪甲下爪真菌症

第6章 世界の爪真菌症市場：治療別

  • 主な調査結果
  • イントロダクション
  • 局所
  • 経口
  • その他

第7章 世界の爪真菌症市場：地域別

  • 主な調査結果
  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Abbott
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Merck & Co., Inc.
  • Moberg Pharma AB
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences
図表

List of Tables:

  • Table 1 Global Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 2 Global Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 3 North America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 4 North America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 5 U.S.: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 6 U.S.: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 7 Canada: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 8 Canada: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 9 Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 10 Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 11 UK: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 12 UK: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 13 France: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 14 France: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 15 Germany: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 16 Germany: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 17 Italy: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 18 Italy: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 19 Spain: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 20 Spain: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 21 Netherlands: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 22 Netherlands: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 23 Russia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 24 Russia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 25 Rest of Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 26 Rest of Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 28 Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 29 China: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 30 China: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 31 India: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 32 India: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 33 Malaysia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 34 Malaysia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 35 Japan: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 36 Japan: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 37 Indonesia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 38 Indonesia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 39 South Korea: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 40 South Korea: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 41 Australia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 42 Australia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 43 Vietnam: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 44 Vietnam: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 45 Rest of Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 46 Rest of Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 47 Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 48 Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 49 Saudi Arabia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 50 Saudi Arabia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 51 UAE: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 52 UAE: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 53 Israel: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 54 Israel: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 55 South Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 56 South Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 57 Rest of Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 58 Rest of Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 59 Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 60 Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 61 Mexico: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 62 Mexico: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 63 Brazil: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 64 Brazil: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 65 Argentina: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 66 Argentina: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • Table 67 Rest of Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • Table 68 Rest of Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)

List of Figures:

  • Figure 1. Global Onychomycosis Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Onychomycosis Market, by Type, 2023 & 2032 (USD Million)
  • Figure 8. Market by Treatment
  • Figure 9. Global Onychomycosis Market, by Treatment, 2023 & 2032 (USD Million)
  • Figure 10. Onychomycosis Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11. Figure 13. Strategic Analysis - Onychomycosis Market
目次
Product Code: PM5011

The global onychomycosis market size is expected to reach USD 5,689.46 million by 2032, according to a new study by Polaris Market Research. The report "Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Market Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The onychomycosis market is experiencing significant growth due to increased recognition of fungal diseases and improved public awareness. This has led to early detection and better understanding of the effects of fungal infections, such as onychomycosis.

In September 2023, the Centers for Disease Control and Prevention (CDC) recognized Fungal Disease Awareness Week (FDAW). Every year, the CDC and its partners participate in initiatives and outreach efforts to raise public awareness of fungal infections. Leading up to FDAW in 2023, various events emphasized the growing challenges, complexities, and significant impacts of fungal diseases.

Furthermore, lasers have received approval from the Food and Drug Administration (FDA), and technological advancements have led to the use of lasers in the treatment of onychomycosis, contributing to the expansion of the market.

As per the Indian Dermatology Online Journal, combining topical therapy with fractional CO2 laser can enhance the effectiveness of onychomycosis treatment. Several factors, such as nail plate thickness, extent and type of onychomycosis, number of sessions, and concurrent therapy, can influence treatment results. Fractional CO2 laser treatment involves creating openings in the nail, which improves the delivery of topical drugs by three to four times over 42 days. Therefore, using fractional CO2 laser as a pre-treatment alongside topical therapy for onychomycosis can be beneficial.

Furthermore, oral treatment for onychomycosis is becoming increasingly popular among patients due to its higher success rates and shorter treatment durations compared to topical antifungals. The main treatment for this fungal infection is oral terbinafine hydrochloride. Many generic manufacturers are introducing oral treatments to address the growing prevalence of onychomycosis.

For instance, in June 2021, Glenmark Pharmaceuticals was granted approval by the U.S. FDA for their therapeutically equivalent and bioequivalent theophylline extended-release tablets, available in 450 mg and 300 mg for the treatment of onychomycosis.

Onychomycosis Market Report Highlights

The distal subungual onychomycosis segment dominated the market. This is due to the rising number of approvals by the FDA in response to the increasing demand for more effective medications for onychomycosis treatment.

The topical segment dominated the market over the forecast period as topical treatments are associated with fewer side effects.

The North America region dominated the market over the forecast period owing to the increased occurrence of the target disease and supportive government policies.

The Asia-Pacific region is expected to grow at the fastest CAGR owing to the limited access to healthcare services, poor hygiene practices, and extensive urbanization.

The global key market players include Bausch Health Companies Inc., Moberg Pharma AB, Abbott, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Zydus Lifesciences and Sun Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the onychomycosis market report based on type, treatment, and region:

Onychomycosis, Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Distal Subungual Onychomycosis
  • Proximal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Others

Onychomycosis, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

  • Topical
  • Oral
  • Others

Onychomycosis, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Vietnam
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Onychomycosis Market Insights

  • 4.1. Onychomycosis Market - Market Snapshot
  • 4.2. Onychomycosis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Demand for Topical Therapies is Driving the Market Growth
      • 4.2.1.2. Rising Advanced Technologies is Driving the Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Presence of Alternative Therapies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Onychomycosis Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Onychomycosis Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Onychomycosis Market, by Type, 2019-2032 (USD Million)
  • 5.3. Distal Subungual Onychomycosis
    • 5.3.1. Global Onychomycosis Market, by Distal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
  • 5.4. Proximal Subungual Onychomycosis
    • 5.4.1. Global Onychomycosis Market, by Proximal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
    • 5.4.2. White Superficial Onychomycosis
      • 5.4.2.1. Global Onychomycosis Market, by White Superficial Onychomycosis, by Region, 2019-2032 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Onychomycosis Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • 6.3. Topical
    • 6.3.1. Global Onychomycosis Market, by Topical, by Region, 2019-2032 (USD Million)
  • 6.4. Oral
    • 6.4.1. Global Onychomycosis Market, by Oral, by Region, 2019-2032 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Onychomycosis Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Onychomycosis Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Onychomycosis Market - North America
    • 7.3.1. North America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
    • 7.3.2. North America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.3.3. Onychomycosis Market - U.S.
      • 7.3.3.1. U.S.: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.3.4. Onychomycosis Market - Canada
      • 7.3.4.1. Canada: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • 7.4. Onychomycosis Market - Europe
    • 7.4.1. Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
    • 7.4.2. Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.3. Onychomycosis Market - UK
      • 7.4.3.1. UK: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.4. Onychomycosis Market - France
      • 7.4.4.1. France: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.4.2. France: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.5. Onychomycosis Market - Germany
      • 7.4.5.1. Germany: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.6. Onychomycosis Market - Italy
      • 7.4.6.1. Italy: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.7. Onychomycosis Market - Spain
      • 7.4.7.1. Spain: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.8. Onychomycosis Market - Netherlands
      • 7.4.8.1. Netherlands: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.9. Onychomycosis Market - Russia
      • 7.4.9.1. Russia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.4.10. Onychomycosis Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.4.10.2. Rest of Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • 7.5. Onychomycosis Market - Asia Pacific
    • 7.5.1. Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.3. Onychomycosis Market - China
      • 7.5.3.1. China: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.3.2. China: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.4. Onychomycosis Market - India
      • 7.5.4.1. India: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.4.2. India: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.5. Onychomycosis Market - Malaysia
      • 7.5.5.1. Malaysia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.6. Onychomycosis Market - Japan
      • 7.5.6.1. Japan: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.7. Onychomycosis Market - Indonesia
      • 7.5.7.1. Indonesia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.8. Onychomycosis Market - South Korea
      • 7.5.8.1. South Korea: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.9. Onychomycosis Market - Australia
      • 7.5.9.1. Australia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.9.2. Australia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.5.10. Onychomycosis Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • 7.6. Onychomycosis Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.6.3. Onychomycosis Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.6.4. Onychomycosis Market - UAE
      • 7.6.4.1. UAE: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.6.5. Onychomycosis Market - Israel
      • 7.6.5.1. Israel: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.6.6. Onychomycosis Market - South Africa
      • 7.6.6.1. South Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.6.7. Onychomycosis Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
  • 7.7. Onychomycosis Market - Latin America
    • 7.7.1. Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.7.3. Onychomycosis Market - Mexico
      • 7.7.3.1. Mexico: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.7.4. Onychomycosis Market - Brazil
      • 7.7.4.1. Brazil: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.7.5. Onychomycosis Market - Argentina
      • 7.7.5.1. Argentina: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
    • 7.7.6. Onychomycosis Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
      • 7.7.6.2. Rest of Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Abbott
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bausch Health Companies Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Cipla Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Merck & Co., Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Moberg Pharma AB
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Novartis AG
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Sun Pharmaceutical Industries Ltd.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Zydus Lifesciences
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development